Phase 2 study of tamibarotene for relapsed acute promyelocytic leukemia (APL) - MPR
Links shared publicly online about this topic.
- 1,547total visits
Phase 2 study of tamibarotene for relapsed acute promyelocytic leukemia (APL) - MPR
empr.com —
CytRx Corporation announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
View full resource at empr.com
Tags: Leukemia, Phase 2 Clinical Trial, Clinical Trial, News
Most Recently Shared on December 7, 2009 at 7:32 pm By:
MPR News: Phase 2 study of tamibarotene for relapsed acute promyelocytic leukemia (APL): CytRx Corporation announce... http://bit.ly/6oQpIW
Advertisement
